Hasil Pencarian - Ricardo D. Parrondo

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

    Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives oleh Ricardo D. Parrondo, Sikander Ailawadhi, Claudio Cerchione

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety

    Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficac... oleh Saurav Das, Sikander Ailawadhi, Taimur Sher, Vivek Roy, Andre Fernandez, Ricardo D. Parrondo

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

    IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies oleh Ricardo D. Parrondo, Madiha Iqbal, Reinhard Von Roemeling, Christina Von Roemeling, Han W. Tun

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review

    Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review oleh Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Victoria Alegria, Asher A. Chanan-Khan, Sikander Ailawadhi

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

    Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis oleh Ricardo D. Parrondo, Keren Sam, Ahsan Rasheed, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan-Khan, Sikander Ailawadhi

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature

    Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature oleh Mizba Baksh, Liuyan Jiang, Unnati Bhatia, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan‐Khan, Sikander Ailawadhi, Ricardo D. Parrondo

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Myelomatous ascites and pleural effusion in relapsed multiple myeloma

    Myelomatous ascites and pleural effusion in relapsed multiple myeloma oleh Mizba Baksh, Ke Li, Liuyan Jiang, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan‐Khan, Sikander Ailawadhi, Ricardo D. Parrondo, Muhamad Alhaj Moustafa

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers

    The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers oleh Sikander Ailawadhi, Meghna Ailawadhi, Navnita Dutta, Ricardo D. Parrondo, Vivek Roy, Taimur Sher, Mizba Baksh, Ahsan Rasheed, Saurav Das, Andre J. Fernandez, Aneel Paulus, Asher A. Chanan‐Khan

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

    Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma oleh Ricardo D. Parrondo, Betsy R. LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J. Flott, Diedre Arrington, Dustin Chapin, Jade Brown, Saurav Das, Vivek Roy, Asher A. Chanan-Khan, Sikander Ailawadhi

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma

    Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma oleh Ricardo D. Parrondo, Zaid Abdel Rahman, Michael G. Heckman, Mikolaj Wieczorek, Liuyan Jiang, Hassan B. Alkhateeb, Mark R. Litzow, Patricia Greipp, Taimur Sher, Leif Bergsagel, Rafael Fonseca, Vivek Roy, Angela Dispenzieri, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Sikander Ailawadhi, James M. Foran

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: